172 related articles for article (PubMed ID: 14631589)
1. [Adverse reactions to immunotherapy in pediatric patients].
Avila Castañón L; Lerma-Ortiz L; Velázquez Armenta Y; del Rio Navarro BE; Sienra Monge JJ
Rev Alerg Mex; 2003; 50(5):182-6. PubMed ID: 14631589
[TBL] [Abstract][Full Text] [Related]
2. [Safety of immunotherapy and skin tests with allergens in children younger than five years].
Rodríguez Pérez N; Ambriz Moreno Mde J
Rev Alerg Mex; 2006; 53(2):47-51. PubMed ID: 16884027
[TBL] [Abstract][Full Text] [Related]
3. Systemic tolerability of specific subcutaneous immunotherapy with index-of-reactivity-standardized allergen extracts administered using clustered regimens: a retrospective, observational, multicenter study.
Serrano P; Justicia JL; Sánchez C; Cimarra M; Fernández-Távora L; Orovitg A; Moreno C; Guerra F; Alvà V
Ann Allergy Asthma Immunol; 2009 Mar; 102(3):247-52. PubMed ID: 19354072
[TBL] [Abstract][Full Text] [Related]
4. Immediate adverse reactions to immunotherapy.
Can D; Demir E; Tanaç R; Gülen F; Yenigün A
J Investig Allergol Clin Immunol; 2003; 13(3):177-80. PubMed ID: 14635467
[TBL] [Abstract][Full Text] [Related]
5. Nonfatal systemic reactions to subcutaneous immunotherapy: a 10-year experience.
Ragusa FV; Passalacqua G; Gambardella R; Campanari S; Barbieri MM; Scordamaglia A; Canonica GW
J Investig Allergol Clin Immunol; 1997; 7(3):151-4. PubMed ID: 9252872
[TBL] [Abstract][Full Text] [Related]
6. [Multicenter drug surveillance of sublingual immunotherapy in allergic patients].
Almagro E; Asensio O; Bartolomé JM; Bosque M; de la Hoz B; Dolz I; Elorza J; Ferreiro M; García JM; Losada E
Allergol Immunopathol (Madr); 1995; 23(4):153-9. PubMed ID: 8553989
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of specific immunotherapy to mosquito bites.
Ariano R; Panzani RC
Eur Ann Allergy Clin Immunol; 2004 Apr; 36(4):131-8. PubMed ID: 15180354
[TBL] [Abstract][Full Text] [Related]
8. Possible relationship between systemic side effects and sensitization to rPar j 2 in allergic patients submitted to an ultra-rush (20 min) sublingual immunotherapy and selected by component resolved diagnosis.
Rossi RE; Monasterolo G; Coco G; Operti D
Int Arch Allergy Immunol; 2005 Oct; 138(2):105-10. PubMed ID: 16174987
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for adverse systemic reactions occurring during immunotherapy with standardized Dermatophagoides farinae extracts.
Ohashi Y; Nakai Y; Tanaka A; Kakinoki Y; Washio Y; Ohno Y; Yamada K; Nasako Y
Acta Otolaryngol Suppl; 1998; 538():113-7. PubMed ID: 9879410
[TBL] [Abstract][Full Text] [Related]
10. [Preventive immunotherapy].
Boquete M; Carballada F; Expósito F; González A
Allergol Immunopathol (Madr); 2000; 28(3):89-93. PubMed ID: 10867376
[TBL] [Abstract][Full Text] [Related]
11. Safety of immunotherapy in patients with rhinitis, asthma or atopic dermatitis using an ultra-rush buildup. A retrospective study.
Cardona R; Lopez E; Beltrán J; Sánchez J
Allergol Immunopathol (Madr); 2014; 42(2):90-5. PubMed ID: 23265265
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of ultra-rush induction, less than one hour, of sublingual immunotherapy in children.
Tripodi S; Di Rienzo Businco A; Benincori N; Scala G; Pingitore G
Int Arch Allergy Immunol; 2006; 139(2):149-52. PubMed ID: 16374025
[TBL] [Abstract][Full Text] [Related]
13. [Study on safty of standardized specific mite-allergen immunotherapy to children with allergic rhinitis and/or asthma].
Wu Y; Long Z; Huang Y; Huang X
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2011 Jul; 25(14):641-4. PubMed ID: 22032122
[TBL] [Abstract][Full Text] [Related]
14. Safety of an ultra-rush immunotherapy build-up schedule with therapeutic vaccines containing depigmented and polymerized allergen extracts.
Casanovas M; Martín R; Jiménez C; Caballero R; Fernández-Caldas E
Int Arch Allergy Immunol; 2006; 139(2):153-8. PubMed ID: 16374026
[TBL] [Abstract][Full Text] [Related]
15. Local and systemic reactions to subcutaneous allergen immunotherapy: Ten years' experience in a pediatric clinic.
Nacaroglu HT; Erdem SB; Sumer O; Karaman S; Unsal Karkıner CS; Asilsoy S; Gunay I; Can D
Ann Allergy Asthma Immunol; 2016 Apr; 116(4):349-53. PubMed ID: 26905639
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of the pediatric aspects of the WHO document and meta-analysis of immunotherapy].
Ibáñez Sendín MD
Allergol Immunopathol (Madr); 2000; 28(3):82-9. PubMed ID: 10867375
[TBL] [Abstract][Full Text] [Related]
17. [Sublingual vs subcutaneous immunotherapy].
Olivé Pérez A
Rev Alerg Mex; 2004; 51(1):29-35. PubMed ID: 15119753
[TBL] [Abstract][Full Text] [Related]
18. Risk of systemic allergic reactions to allergen immunotherapy in a pediatric allergy clinic in Turkey.
Bahceci Erdem S; Nacaroglu HT; Karaman S; Unsal Karkıner CS; Gunay I; Dogan D; Asilsoy S; Altınoz S; Can D
Int J Pediatr Otorhinolaryngol; 2016 May; 84():55-60. PubMed ID: 27063754
[TBL] [Abstract][Full Text] [Related]
19. Retrospective study of specific immunotherapy - what should be done in the future.
Milavec-Puretić V; Lipozencić J; Ledić-Drvar D; Smigovec E; Milavec D
Acta Dermatovenerol Croat; 2007; 15(4):221-7. PubMed ID: 18093449
[TBL] [Abstract][Full Text] [Related]
20. The pattern of indoor and outdoor respiratory allergens in asthmatic adult patients in a humid and desert newly developed country.
Sattar HA; Mobayed H; al-Mohammed AA; Ibrahim AS; Jufairi AA; Balamurugan P; Mary VP; Bener A
Eur Ann Allergy Clin Immunol; 2003 Oct; 35(8):300-5. PubMed ID: 14653049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
